CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, announced its participation in a Virtual Investor KOL Connect segment. The event featured key members of the CNS management team, including:
- John Climaco, Chief Executive Officer
- Dr. Sandra Silberman, Chief Medical Officer
- Dr. Don Picker, Chief Scientific Officer
Additionally, Dr. Samuel Goldlust, a leading Neuro-Oncologist and Key Opinion Leader, joined the segment. Dr. Goldlust currently serves as the Medical Director of Neuro-Oncology at Saint Luke's Health System and was previously an investigator in CNS's global potentially pivotal study of Berubicin.
The segment covered a corporate overview, discussed the unmet need in glioblastoma multiforme (GBM), and explored the opportunities for CNS Pharmaceuticals in this field.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), un'azienda biofarmaceutica focalizzata sullo sviluppo di nuovi trattamenti per i tumori del cervello e del sistema nervoso centrale, ha annunciato la sua partecipazione a un segmento Virtual Investor KOL Connect. L'evento ha presentato membri chiave del team di gestione di CNS, tra cui:
- John Climaco, Amministratore Delegato
- Dr. Sandra Silberman, Direttore Medico
- Dr. Don Picker, Direttore Scientifico
In aggiunta, il Dr. Samuel Goldlust, un neuro-oncologo di spicco e leader d'opinione, ha partecipato al segmento. Il Dr. Goldlust attualmente ricopre il ruolo di Direttore Medico di Neuro-Oncologia presso il Saint Luke's Health System ed è stato in precedenza un investigatore nello studio globale potenzialmente determinante di CNS su Berubicin.
Il segmento ha trattato una panoramica aziendale, discusso del bisogno insoddisfatto nel glioblastoma multiforme (GBM), ed esplorato le opportunità per CNS Pharmaceuticals in questo campo.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), una compañía biofarmacéutica enfocada en desarrollar nuevos tratamientos para cánceres del cerebro y del sistema nervioso central, anunció su participación en un segmento Virtual Investor KOL Connect. El evento contó con miembros clave del equipo directivo de CNS, incluyendo:
- John Climaco, Director Ejecutivo
- Dr. Sandra Silberman, Directora Médica
- Dr. Don Picker, Director Científico
Además, el Dr. Samuel Goldlust, un neuro-oncólogo destacado y líder de opinión, se unió al segmento. El Dr. Goldlust actualmente se desempeña como Director Médico de Neuro-Oncología en el sistema de salud Saint Luke y anteriormente fue investigador en el estudio global potencialmente decisivo de CNS sobre Berubicin.
El segmento cubrió una visión general de la empresa, discutió la necesidad no satisfecha en glioblastoma multiforme (GBM), y exploró las oportunidades para CNS Pharmaceuticals en este campo.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)는 뇌와 중추 신경계 암 치료를 위한 새로운 치료법 개발에 중점을 두고 있는 생명공학 회사로, Virtual Investor KOL Connect 세그먼트에 참여한다고 발표했습니다. 이 이벤트는 CNS 경영진의 주요 멤버들이 등장했습니다:
- John Climaco, CEO(최고경영자)
- Dr. Sandra Silberman, CMO(최고의료책임자)
- Dr. Don Picker, CSO(최고과학책임자)
또한 주요 신경종양학자이자 주요 의견 리더인 Samuel Goldlust 박사가 세그먼트에 참여했습니다. Goldlust 박사는 현재 Saint Luke's Health System의 신경종양학 의료 감독으로 재직 중이며, 이전에 CNS의 글로벌 잠재적 결정적 연구에서 Berubicin의 조사자로 활동했습니다.
이 세그먼트는 회사 개요를 다루고, 다형성 교모세포종 (GBM)에서의 충족되지 않은 필요성을 논의하며, CNS Pharmaceuticals에 대한 기회를 탐색했습니다.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), une société biopharmaceutique axée sur le développement de nouveaux traitements pour les cancers du cerveau et du système nerveux central, a annoncé sa participation à un segment de Virtual Investor KOL Connect. L'événement a présenté des membres clés de l'équipe de direction de CNS, y compris :
- John Climaco, Directeur Général
- Dr. Sandra Silberman, Directrice Médicale
- Dr. Don Picker, Directeur Scientifique
De plus, le Dr. Samuel Goldlust, un neuro-oncologue de premier plan et leader d'opinion, a rejoint le segment. Le Dr. Goldlust est actuellement Directeur Médical en Neuro-Oncologie au sein du système de santé Saint Luke et a été préalablement investigateur dans l'étude mondiale potentiellement décisive de CNS sur Berubicin.
Le segment a couvert un aperçu de l'entreprise, discuté du besoin non satisfait dans le glioblastome multiforme (GBM) et exploré les opportunités pour CNS Pharmaceuticals dans ce domaine.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuartiger Behandlungen für Tumoren des Gehirns und des zentralen Nervensystems spezialisiert hat, gab seine Teilnahme an einem Segment von Virtual Investor KOL Connect bekannt. Die Veranstaltung beinhaltete wichtige Mitglieder des Managementteams von CNS, darunter:
- John Climaco, Chief Executive Officer
- Dr. Sandra Silberman, Chief Medical Officer
- Dr. Don Picker, Chief Scientific Officer
Darüber hinaus nahm Dr. Samuel Goldlust, ein führender Neuro-Onkologe und Key Opinion Leader, an dem Segment teil. Dr. Goldlust ist derzeit als Medizinischer Direktor für Neuro-Onkologie am Saint Luke's Health System tätig und war zuvor ein Prüfer in der globalen potenziell entscheidenden Studie von CNS über Berubicin.
Das Segment behandelte einen Unternehmensüberblick, diskutierte den ungedeckten Bedarf bei glioblastoma multiforme (GBM) und erkundete die Möglichkeiten für CNS Pharmaceuticals in diesem Bereich.
- Participation in Virtual Investor KOL Connect segment, potentially increasing investor awareness
- Involvement of a leading Neuro-Oncologist and Key Opinion Leader in the segment
- Focus on addressing unmet needs in glioblastoma multiforme (GBM), a challenging area in oncology
- None.
Segment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust
HOUSTON, TX / ACCESSWIRE / October 10, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment. The segment can be accessed here.
As part of the event, John Climaco, Chief Executive Officer, Dr. Sandra Silberman, Chief Medical Officer, Dr. Don Picker, Chief Scientific Officer, and Dr. Samuel Goldlust, a leading Neuro-Oncologist and Key Opinion Leader who currently serves as the Medical Director of Neuro-Oncology at Saint Luke's Health System and previously an investigator in the Company's global potentially pivotal study of Berubicin, provided a corporate overview, discussed the unmet need in glioblastoma multiforme (GBM) and discussed the CNS opportunity.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What was the purpose of CNS Pharmaceuticals' (CNSP) participation in the Virtual Investor KOL Connect segment?
Who were the key participants from CNS Pharmaceuticals (CNSP) in the Virtual Investor KOL Connect segment?
What is the significance of Dr. Samuel Goldlust's participation in the CNS Pharmaceuticals (CNSP) Virtual Investor KOL Connect segment?
What is the main focus of CNS Pharmaceuticals' (CNSP) research and development?
